Mindset Pharma Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James Andre-Charles Lanthier
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 217 Queen Street West Toronto ON Canada M5V 0R2
- IPO Date
- Feb 8, 2021
- Website
- mindsetpharma.com
- Similar Companies
- Business
- Mindset Pharma Inc. (Ticker: MSSTF) is a clinical-stage biotechnology company focused on developing novel psychedelic therapeutics for neuropsychiatric disorders and unmet medical needs. The company advances proprietary next-generation serotonin 5-HT2A receptor agonists and related compounds, including its lead candidate MSP-401 for anxiety disorder associated with adjustment reaction to a life-threatening or debilitating medical condition; additional pipeline assets such as MSP-778 targeting obesity and metabolic disorders, and earlier-stage programs for treatment-resistant depression and substance use disorders. Its platform emphasizes rapid-acting, orally bioavailable molecules designed to improve safety, efficacy, and patient compliance compared to traditional psychedelics like psilocybin or LSD. Founded in 2020 and headquartered in Toronto, Ontario, Canada, Mindset Pharma operates primarily in North America with research and development activities supported by contract manufacturing and clinical trial partners across the region. In late 2023, the company completed a strategic merger with Global Drug Development Centre China (GDCC), forming Mindset Pharma (Nanshan) Co., Ltd., a wholly-owned subsidiary in Shenzhen, China, to accelerate clinical development of its pipeline in Asia; this alliance enhances manufacturing capabilities and regulatory expertise for global expansion. Recent advancements include dosing the first patient in the Phase 2b study of MSP-401 in 2024 and initiating preclinical work on novel analogs, positioning the company for potential Phase 3 transitions amid growing interest in psychedelic medicine.
Mindset Pharma Announces Closing of Arrangement
Mindset Pharma Announces Receipt of Final Order
Mindset Pharma Announces Shareholder Approval of Arrangement
Mindset Pharma Provides Clarifying Disclosure in Connection with Proposed Plan of Arrangement
Mindset Pharma Announces Mailing of Circular and Receipt of Interim Order
Mindset Pharma to be acquired by Otsuka Pharmaceutical in all-cash deal
Otsuka Pharmaceutical to Acquire Mindset Pharma
Mindset Pharma's Phase 2 psilocin prodrug study gets green light from UK regulators
Mindset Pharma files two international patent applications under the Patent Cooperation Treaty
Mindset Pharma CEO discusses expansion of drug discovery efforts into novel non-hallucinogenic therapeutics
Mindset Pharma and PharmAla complete first sale of pharmaceutical-grade psilocybin into growing Australian market via sales partnership
Mindset Pharma receives another allowance for US patent application expanding composition of matter for Family 1 psilocybin analogs
Mindset Pharma receives allowance for US patent application covering lead psychedelic therapeutic candidate
Mindset Pharma to Participate in Upcoming Conferences in December 2022
Mindset Pharma spotlights recent achievements ahead of ‘even more exciting 2023' in shareholder update
Mindset Pharma and PharmAla Biotech forge exclusive sales agreement
Mindset Pharma presents data showing its psilocin prodrug is better tolerated than psilocybin
Mindset Pharma chooses pair of psychedelic drug candidates to move Family 2 program forward
Mindset Pharma provides strategic intellectual property license to Cybin for preclinical psychedelic drug research
Mindset Pharma to advance lead psychedelic drug candidate MSP-1014 into Phase 1 first-in-human trial